251 related articles for article (PubMed ID: 17899549)
21. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice.
Dai Z; Konieczny BT; Baddoura FK; Lakkis FG
J Immunol; 1998 Aug; 161(4):1659-63. PubMed ID: 9712028
[TBL] [Abstract][Full Text] [Related]
22. Restoring function in exhausted CD8 T cells during chronic viral infection.
Barber DL; Wherry EJ; Masopust D; Zhu B; Allison JP; Sharpe AH; Freeman GJ; Ahmed R
Nature; 2006 Feb; 439(7077):682-7. PubMed ID: 16382236
[TBL] [Abstract][Full Text] [Related]
23. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis.
Ding H; Wu X; Gao W
Clin Immunol; 2005 May; 115(2):184-91. PubMed ID: 15885642
[TBL] [Abstract][Full Text] [Related]
25. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice.
Gotsman I; Grabie N; Dacosta R; Sukhova G; Sharpe A; Lichtman AH
J Clin Invest; 2007 Oct; 117(10):2974-82. PubMed ID: 17853943
[TBL] [Abstract][Full Text] [Related]
26. Induction of allograft tolerance in the absence of Fas-mediated apoptosis.
Li XC; Li Y; Dodge I; Wells AD; Zheng XX; Turka LA; Strom TB
J Immunol; 1999 Sep; 163(5):2500-7. PubMed ID: 10452986
[TBL] [Abstract][Full Text] [Related]
27. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Iwai Y; Ishida M; Tanaka Y; Okazaki T; Honjo T; Minato N
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12293-7. PubMed ID: 12218188
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y; Starke A; Wüthrich RP
Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
[TBL] [Abstract][Full Text] [Related]
29. PD-1 inhibits antiviral immunity at the effector phase in the liver.
Iwai Y; Terawaki S; Ikegawa M; Okazaki T; Honjo T
J Exp Med; 2003 Jul; 198(1):39-50. PubMed ID: 12847136
[TBL] [Abstract][Full Text] [Related]
30. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.
Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW
Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786
[TBL] [Abstract][Full Text] [Related]
31. Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege.
Cheng X; Dai H; Wan N; Moore Y; Vankayalapati R; Dai Z
Transplantation; 2009 Jun; 87(12):1778-86. PubMed ID: 19543053
[TBL] [Abstract][Full Text] [Related]
32. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome.
Kobayashi M; Kawano S; Hatachi S; Kurimoto C; Okazaki T; Iwai Y; Honjo T; Tanaka Y; Minato N; Komori T; Maeda S; Kumagai S
J Rheumatol; 2005 Nov; 32(11):2156-63. PubMed ID: 16265694
[TBL] [Abstract][Full Text] [Related]
33. Adoptive transfer of transplantation tolerance mediated by CD4+CD25+ and CD8+CD28- regulatory T cells induced by anti-donor-specific T-cell vaccination.
Wang J; Zhang L; Tang J; Jiang S; Wang X
Transplant Proc; 2008 Jun; 40(5):1612-7. PubMed ID: 18589160
[TBL] [Abstract][Full Text] [Related]
34. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Blank C; Gajewski TF; Mackensen A
Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
[TBL] [Abstract][Full Text] [Related]
35. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
36. Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism.
Sugita S; Usui Y; Horie S; Futagami Y; Yamada Y; Ma J; Kezuka T; Hamada H; Usui T; Mochizuki M; Yamagami S
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):263-72. PubMed ID: 18775867
[TBL] [Abstract][Full Text] [Related]
37. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Butte MJ; Keir ME; Phamduy TB; Sharpe AH; Freeman GJ
Immunity; 2007 Jul; 27(1):111-22. PubMed ID: 17629517
[TBL] [Abstract][Full Text] [Related]
38. Limited costimulatory molecule expression on renal tubular epithelial cells impairs T cell activation.
Waeckerle-Men Y; Starke A; Wahl PR; Wüthrich RP
Kidney Blood Press Res; 2007; 30(6):421-9. PubMed ID: 17975322
[TBL] [Abstract][Full Text] [Related]
39. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
[TBL] [Abstract][Full Text] [Related]
40. Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells.
Chen C; Qu QX; Huang JA; Zhu YB; Ge Y; Wang Q; Zhang XG
Immunobiology; 2007; 212(3):159-65. PubMed ID: 17412283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
